Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human tumor antigens recognized by T cells

P F Robbins1, Y Kawakami

  • 1Surgery Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD 20892-1502, USA. pfr@helix.nih.gov

Current Opinion in Immunology
|October 1, 1996
PubMed
Summary

Tumor-reactive T cells can shrink tumors, as seen in melanoma patients receiving adoptive immunotherapy. Researchers have identified genes for melanoma antigens, now being tested in clinical vaccine trials for tumor regression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Cancer research·2001
Same author

Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2001
Same author

N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4(+) T cells.

European journal of immunology·2001
Same author

A listing of human tumor antigens recognized by T cells.

Cancer immunology, immunotherapy : CII·2001
Same author

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Proceedings of the National Academy of Sciences of the United States of America·2001

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Tumor-reactive T cells demonstrate in vivo tumor regression capabilities.
  • Clinical responses to adoptive immunotherapy highlight the potential of tumor-infiltrating lymphocytes in melanoma treatment.

Purpose of the Study:

  • To evaluate the efficacy of tumor regression antigens identified through gene isolation.
  • To assess the potential of these antigens in clinical vaccine trials for melanoma.

Main Methods:

  • Isolation of genes encoding antigens recognized by melanoma-reactive T cells.
  • Evaluation of isolated gene products as tumor regression antigens in clinical vaccine trials.

Main Results:

  • Identification of multiple genes encoding melanoma antigens.

Related Experiment Videos

  • Initiation of clinical vaccine trials to test these antigens for tumor regression.

    • Conclusions:

    • Tumor-infiltrating lymphocytes and identified melanoma antigens show promise for cancer immunotherapy.
    • Further clinical evaluation is ongoing to establish the therapeutic potential of these antigens in vaccine-based strategies.